Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7986183 | 1.00 | TACR1 (0.74) | TACR1CCR3 | |
| SCHEMBL7934839 | 0.99 | TACR1 (0.73) | TACR1CCR3 | |
| SCHEMBL7926175 | 0.98 | TACR1 (0.72) | TACR1CCR3 | |
| SCHEMBL9055871 | 0.93 | TACR1 (0.74) | TACR1CCR3 | |
| SCHEMBL7932594 | 0.91 | CCR3 (0.76) | TACR1CCR3 | |
| SCHEMBL7926005 | 0.91 | CCR3 (0.76) | TACR1CCR3 | |
| SCHEMBL7934765 | 0.89 | TACR1 (0.74) | TACR1CCR3 | |
| SCHEMBL7934814 | 0.89 | TACR1 (0.60) | TACR1CCR3 | |
| SCHEMBL9054676 | 0.88 | TACR1 (0.58) | TACR1CCR3 | |
| SCHEMBL7932651 | 0.87 | TACR1 (0.67) | TACR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916797-B2 | α-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2005-07-12 | — | — | US | disclosed |
| US-20030220323-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2003-11-27 | — | — | US | disclosed |
| EP-1110958-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | UCB, S.A. (BE) | 2001-06-27 | — | — | EP | disclosed |
| US-6191135-B1 | Neurokinin antagonists | BOEHRINGER INGELHEIM KG (DE) | 2001-02-20 | — | — | US | disclosed |
| US-5985881-A | TREATMENT AND PREVENTION OF RESPIRATORY DISORDERS, INFLAMMATORY EYE DISEASES, INFLAMMATORY SKIN DISEASES, INTESTINAL DISORDERS, OTHER INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM KG (DE) | 1999-11-16 | — | — | US | disclosed |
| WO-1996008480-A1 | NEUROKININ ANTAGONISTS | BOEHRINGER INGELHEIM KG (DE) | 1996-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220323-A1 | Alpha-arylethylpiperazine derivatives as neurokinin antagonists | TACR1, TACR2, NPSR1 | TACR1 1/4885CCR3 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.